Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.70 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.70 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.70 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.70 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 6/20 | 0.44 |
| ▸ | CA2 | P00918 | 6/20 | 0.44 |
| ▸ | CA12 | O43570 | 5/20 | 0.44 |
| ▸ | CA9 | Q16790 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19096540 | 0.92 | MEN1 (0.73) | MEN1KMT2AABCC3ABCC4ABCB11 | |
| SCHEMBL20920719 | 0.91 | MEN1 (0.71) | MEN1KMT2AABCC3ABCC4ABCB11 | |
| SCHEMBL14521888 | 0.89 | KMT2A (0.69) | MEN1KMT2AABCC3ABCC4ABCB11 | |
| SCHEMBL20920718 | 0.89 | CYP2C9 (0.75) | MEN1KMT2AABCC3ABCC4ABCB11 | |
| SCHEMBL14371709 | 0.88 | MEN1 (0.64) | MEN1KMT2AABCC3ABCC4ABCB11 | |
| SCHEMBL11198683 | 0.87 | CYP2C9 (0.71) | MEN1KMT2AABCC3ABCC4ABCB11 | |
| SCHEMBL5389225 | 0.86 | MEN1 (0.60) | MEN1KMT2AABCC3ABCC4ABCB11 | |
| SCHEMBL28623676 | 0.85 | KMT2A (0.64) | MEN1KMT2AABCC3ABCC4ABCB11 | |
| SCHEMBL14544499 | 0.84 | MEN1 (0.63) | MEN1KMT2AABCC3ABCC4ABCB11 | |
| SCHEMBL28605437 | 0.84 | KMT2A (0.62) | MEN1KMT2AABCC3ABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310462-A1 | COMBINATION DRUG FOR THE CONTROL AND MANAGEMENT OF TYPE 2 DIABETES MELLITUS | LABORATORIOS SILANES S.A. DE C.V. (MX) | 2023-10-05 | — | — | US | disclosed |
| US-20220265776-A1 | COMBINATION | GENESIS PHARMA SA (GR) | 2022-08-25 | — | — | US | disclosed |
| US-20210340133-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2021-11-04 | — | — | US | disclosed |
| US-20190283010-A1 | EX VIVO METHODS FOR PREDICTING AND CONFIRMING IN VIVO METABOLISM OF PHARMACEUTICALLY ACTIVE COMPOUNDS | EMPIRIKO CORPORATION | 2019-09-19 | — | — | US | disclosed |
| WO-2008028914-A1 | COMBINATION TREATMENT FOR DIABETES MELLITUS | NYCOMED GMBH (DE) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190283010-A1 | EX VIVO METHODS FOR PREDICTING AND CONFIRMING IN VIVO METABOLISM OF PHARMACEUTICALLY ACTIVE COMPOUNDS | CYP3A43, CYP3A4, CYP2D6 | MEN1 2675/4885KMT2A 4014/4885ABCC3 514/4885 |
| US-20210340133-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, GLP1R, SLC5A2 | MEN1 2853/4885KMT2A 706/4885ABCC3 973/4885 |
| US-20230310462-A1 | COMBINATION DRUG FOR THE CONTROL AND MANAGEMENT OF TYPE 2 DIABETES MELLITUS | DPP4, DPP7, DPP3 | MEN1 2239/4885KMT2A 967/4885ABCC3 163/4885 |
| US-20220265776-A1 | COMBINATION | GLP1R, IAPP, GCG | MEN1 594/4885KMT2A 3722/4885ABCC3 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.